Baird Financial Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Baird Financial Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,793	Closed	-$1.02M	–	1826
2023 Q3	$1.02M	Sell	8,793 -9,447	-52%	-$1.02M	﹤0.01%	1110
2023 Q2	$1.88M	Buy	18,240 +12,976	+247%	+$1.37M	0.01%	927
2023 Q1	$575K	Buy	+5,264	New	+$582K	﹤0.01%	1268
2022 Q1	–	Sell	-1,925	Closed	-$207K	–	1962
2021 Q4	$207K	Buy	+1,925	New	+$210K	﹤0.01%	1812
2021 Q3	–	Sell	-2,644	Closed	-$248K	–	1953
2021 Q2	$248K	Buy	+2,644	New	+$243K	﹤0.01%	1626
2020 Q3	–	Sell	-8,830	Closed	-$491K	–	1607
2020 Q2	$491K	Buy	+8,830	New	+$378K	﹤0.01%	1147

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Baird Financial Group's HZNP Position: Q4 2023 in Review

Baird Financial Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 8,793 shares — an estimated $1.02M sold.

Baird Financial Group first reported a position in HZNP in Q2 2020 and held it in 6 quarters. The position peaked at $1.88M in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Baird Financial Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Baird Financial Group sold 8,793 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.02M.
Baird Financial Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 6 quarters.
Baird Financial Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.88M in Q2 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Baird Financial Group's 13F filing for Q4 2023, filed 14 Feb 2024.